Recently, several studies have reported that PI3K-AKT pathway as a key downstream signalling pathway is involved in m6A dysregulation in various cancers including endometrial cancer [32], prostate cancer [33] and acute myeloid leukemia (AML) [34]. This evidence concerns the gene AKT1 and prostate carcinoma.